Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 201

Drug Profile

IMM 201

Alternative Names: DAR 901; Heat-killed Mycobacterium vaccae strain NCTC 11659; IMM-201; SRL 172

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Silence Therapeutics
  • Developer Aeras; Geisel School of Medicine; Immodulon Therapeutics; Tokyo Medical and Dental University; University of Colorado at Boulder
  • Class Adjuvants; Antineoplastics; Antivirals; Tuberculosis vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • No development reported Post-traumatic stress disorders
  • Discontinued Asthma; Atopic dermatitis; Hepatitis B; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Prostate cancer; Renal cancer; Seasonal allergic rhinitis; Small cell lung cancer

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (Injection)
  • 08 Apr 2021 IMM 201 is still in phase II trials for Mycobacterium tuberculosis in Tanzania (NCT02712424)
  • 01 Feb 2020 Dartmouth-Hitchcock Medical Center at the Geisel School of Medicine completes a phase II DAR-PIA trial in Mycobacterium tuberculosis in Tanzania (NCT02712424)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top